Increased user fee rates in Canada from 1 April
This article was originally published in SRA
Health Canada has published its updated user fee rates that will apply from 1 April for regulatory activities covering the drug and medical device sectors1. The new rates represent a significant hike compared with current rates, which have not been raised since their introduction in the 1990s.
You may also be interested in...
The UK’s deployment of COVID-19 vaccines has left vaccine manufacturers worried about emerging discussions on dosing strategies that may not be supported by authorized labeling or published clinical data.
Existing importers and manufacturers of certain medical devices can continue marketing their products for six months or until the Indian medtech regulator makes a final decision on their pending licensing applications.
Differences between how Australia and the EU define “central circulatory system” has resulted in different risk classification levels being assigned to some devices in the two jurisdictions.